France will administer Pfizer’s corona virus antiviral drug among the citizens to aid against Covid-19 infection. The country will also be part of twenty-seven European states who approved the first pill for treating Omicron variant infections.
The country ranks high among the world’s daily Covid cases report, and virus related critical care hospitalization is expected as novel corona virus infection surges worldwide.
Moreover, France lifts the corona virus curbs because they want the citizens to learn to live with the novel corona virus.
Wearing masks in disclosed places is no longer mandatory in France; huge crowds, including concerts and sports events, are allowed. The French government also lifts work from home and part-time job options next week.
Meanwhile, the French Health Ministry emphasizes that Pfizer containing drug Paxlovid will be offered from Friday (4 February); France has successfully received its first 10,000 doses of the Pfizer drug Paxlovid.
According to European Medicines Agency, the treatment will be given to adults suffering from symptoms of the corona virus, who don’t require oxygen or who are suffering from severe disease. Supplies of the drug remain limited worldwide.
The EMA recommended that Paxlovid be authorized for use, saying it would help Covid patients who are suffering from serious illness and being hospitalized.
In December, the drug Paxlovid was cleared by regulators in the US and Britain. An antiviral pill to fight against the Omicron variant from Merck is expected to soon be authorized.
Both drugs seem effective against omicron because they do not target the spike protein where most of the variant’s problematic mutations reside.
